Go Pro
NASDAQ:SCLX

Scilex Q1 2026 Earnings Report

Scilex logo
$8.30 +0.49 (+6.33%)
As of 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Scilex EPS Results

Actual EPS
-$4.76
Consensus EPS
-$0.34
Beat/Miss
Missed by -$4.42
One Year Ago EPS
N/A

Scilex Revenue Results

Actual Revenue
$8.61 million
Expected Revenue
$15.00 million
Beat/Miss
Missed by -$6.39 million
YoY Revenue Growth
N/A

Scilex Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 20, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Scilex's Q2 2026 earnings is estimated for Wednesday, September 2, 2026, based on past reporting schedules

Earnings Documents

Scilex Earnings Headlines

Forget SpaceX, this is Elon’s Next Breakthrough
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI patent could trigger a wealth wave they're calling his biggest breakthrough yet. They're tracking a market pattern with a 100% historical track record of major gains, and they believe it's about to collide with this invention. The last time it triggered, investors had a chance to turn $10,000 into $350,000 in roughly 12 months.tc pixel
Scilex secures major growth capital equity investment
See More Scilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email.

About Scilex

Scilex (NASDAQ:SCLX) Holdings, Inc. (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways. The company’s pipeline includes additional topical and localized therapies designed to address a range of acute and chronic pain indications without the abuse potential associated with opioid medications. Scilex pursues both in-house research and selective licensing partnerships to broaden its offering.

Headquartered in San Diego, California, Scilex operates primarily in the U.S. market, where it works with healthcare providers, specialty pharmacies and distributors to ensure patient access to its products. The company’s management team brings experience in pharmaceutical development, regulatory affairs and commercial operations, supporting Scilex’s strategy of targeted growth within the pain therapeutics space.

View Scilex Profile